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Gallium is an ironmimeticwhich has recently been repurposed as an antibacterial agent due to its capability to disrupt bacterial iron
metabolism. In this study, the antibacterial activity of galliumnitrate [Ga(NO3)3]was investigated in complement-free human serum
(HS) on 55 Pseudomonas aeruginosa clinical isolates from cystic fibrosis and non-cystic fibrosis patients. The susceptibility of P.
aeruginosa to Ga(NO3)3 in HS was dependent on the bacterial ability to acquire iron from serum binding proteins (i.e., transfer-
rin). The extent of serum protein degradation correlated well with P. aeruginosa growth in HS, while pyoverdine production did
not. However, pyoverdine-deficient P. aeruginosa strains were unable to grow in HS and overcome iron restriction, albeit capa-
ble of releasing proteases. Predigestion of HS with proteinase K promoted the growth of all strains, irrespective of their ability to
produce proteases and/or pyoverdine. TheMICs of Ga(NO3)3 were higher in HS than in an iron-poor Casamino Acids medium,
where proteolysis does not affect iron availability. Coherently, strains displaying high proteolytic activity were less susceptible to
Ga(NO3)3 in HS. Our data support a model in which both pyoverdine and proteases affect the response of P. aeruginosa to
Ga(NO3)3 in HS. The relatively high Ga(NO3)3 concentration required to inhibit the growth of highly proteolytic P. aeruginosa
isolates in HS poses a limitation to the potential of Ga(NO3)3 in the treatment of P. aeruginosa bloodstream infections.
Pseudomonas aeruginosa is a major nosocomial pathogen andthe leading cause of chronic lung infection in cystic fibrosis
(CF) patients. As for other pathogens, P. aeruginosa is faced with
severe iron limitation in the mammalian host, since iron is with-
held by the host’s iron-binding proteins, such as transferrin (Tf) in
serum and lactoferrin in mucosal secretions (1). Iron acquisition
is crucial for P. aeruginosa pathogenicity, as inferred by the pres-
ence of multiple iron uptake systems, including the production of
siderophores (i.e., pyoverdine [PVD] and pyochelin) (2, 3) and
several proteases that cleave the host’s iron binding proteins,
thereby increasing iron availability in vivo (4).
The loss of efficacy of conventional antibiotic therapies for P.
aeruginosa infection calls for the development of novel therapeu-
tic options aimed at inhibiting both acute and chronic infections.
In recent years, attention has been directed to antimicrobial ap-
proaches targeting bacterial iron metabolism, since iron is essen-
tial for bacteria to cause infection (5, 6). Due to its chemical
similarity with iron, the metal gallium (Ga3) perturbs several
iron-dependent biological processes (7), thereby inhibiting the
growth of many bacterial species, including P. aeruginosa (8–12).
Therefore, the repurposing of gallium-based drugs for antibacte-
rial therapy has attracted recent interest, as testified by the initia-
tion of a clinical trial aimed at monitoring the effect of Ganite, the
FDA-approved Ga(NO3)3 formulation, administered to CF pa-
tients chronically infected by P. aeruginosa (13, 14). Since sepsis
represents a frequent complication of P. aeruginosa primary infec-
tion, with life-threatening consequences and a heavy impact on
health care (15), drugs that counteract the bloodstream dissemi-
nation of P. aeruginosa are needed.
The aim of the present study was to test the efficacy of
Ga(NO3)3 in inhibiting P. aeruginosa growth in complement-free
human serum (HS), which provides a vehicle for systemic dissem-
ination of infection.We demonstrate that the growth of P. aerugi-
nosa in HS is dependent on the ability of individual strains to
release proteases that cleave serum proteins, including Tf, as well
as on the production of the PVD siderophore, ultimately causing
iron release from serum proteins and stimulation of bacterial
growth. This phenomenon should be taken into account when
assessing the antibacterial efficacy of gallium, since the ability of
bacteria to retrieve iron from the host would counteract growth
inhibition based on iron mimetism (8–11).
MATERIALS AND METHODS
Bacterial strains, media, and chemicals. The 55 P. aeruginosa clinical
isolates used in this study are listed in Table S1 in the supplemental ma-
terial. The collection included 27 isolates from respiratory secretions of
CF patients and 28 from other pathological samples from non-CF pa-
tients, also including the reference strains PAO1 (ATCC 15692) and PA14
(16). P. aeruginosa was grown in iron-free Casamino Acids medium
(DCAA) (17), Mueller-Hinton broth (MH; Difco), or HS supplemented
or not with the appropriate FeCl3 concentration. Control experiments
were conducted in HS that was predigested for 18 h at 37°C with 100
g/ml proteinase K (Promega) and then inactivated for 30 min at 65°C.
CompleteHS hydrolysis has been qualitatively verified by SDS-PAGE (see
Fig. S1 in the supplemental material).
HS was obtained from 125 healthy donors, following illustration, ap-
proval, and subscription of informed consent. Complement was inacti-
vated by incubation at 56°C for 30 min, and the bulk of HS was sterilized
by filtration as previously described (18) and then stored at 4°C until
used. Bulk HS chemistry was as follows: total serum proteins, 80 mg/ml;
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total iron, 0.70 g/ml; ferritin, 0.243 g/ml; Tf, 2.63 mg/ml (64 M total
iron-binding sites); total iron binding capacity, 4.27 mg/ml (20% Tf sat-
uration, equivalent to 51.5Munsaturated iron binding sites). Ga(NO3)3
was purchased from Sigma-Aldrich.
Bacterial growth and PVDdeterminations.Bacterial growth (optical
density at 600 nm [OD600]) was monitored in 96-well microtiter plates
using aWallac 1420Victor3Vmultilabel plate reader (PerkinElmer). PVD
levels in culture supernatants were measured as the OD405 upon dilution
in 100 mM Tris-HCl (pH 8) (19).
PVD purification. For PVD purification, the methods of Meyer et al.
(20) were used with minor modifications. P. aeruginosa pchD was grown
in DCAA for 18 h. The culture supernatant was purified by filtration
through a Sep-Pak C18 Vac-Cartridge 3cc (Waters). After the polymer
packing was solvated with 10 hold-up volumes of 50% (vol/vol) metha-
nol, the cartridge was flushedwith 10 hold-up volumes of double-distilled
water. The filtered culture supernatant containing PVD was loaded, and
the unwanted components were eluted with double-distilled water. PVD
was then eluted with a small quantity of 50% (vol/vol) methanol, evapo-
rated to dryness in a desiccator, and dissolved in a small volumeof double-
distilled water. The PVD concentration was determined by spectrophoto-
metricmeasurement of the apo form at OD405 (ε 1.4 10
4M1 cm1)
(21).
Ga(NO3)3 susceptibility tests. Ga(NO3)3 activity was tested in 96-well
microtiter plates. Briefly, P. aeruginosa clinical isolates were grown over-
night at 37°C in DCAA supplemented with 40MFeCl3 and then diluted
to an OD600 of 0.01 in 200 l (final volume) of HS or DCAA containing
increasing Ga(NO3)3 concentrations (0 to 128 M). Microtiter plates
were incubated for up to 48 h at 37°C with shaking (120 rpm). Suscepti-
bility assays in MH were performed using a Ga(NO3)3 concentration
range of 0 to 512 M and a standard broth microdilution experimental
procedure (22). MICs were defined as the lowest Ga(NO3)3 concentra-
tions that completely inhibited P. aeruginosa growth, as detected by visual
inspection of the plates. Each strain was tested in at least two independent
experiments.
Quantification of hydrolyzed HS proteins. Supernatants from P.
aeruginosa cultures in HS were analyzed both quantitatively and qualita-
tively to determine HS protein hydrolysis. For quantitative measure-
ments, supernatants were supplemented with 13% trichloroacetic acid
(TCA) in order to precipitate nonhydrolyzed proteins (23). Subsequently,
the hydrolyzed (i.e., TCA-nonprecipitable) protein fraction was quanti-
fied by the Lowry assay (24). For qualitative measurements, supernatants
were diluted 1:16 in gel loading buffer (0.25 M Tris-HCl, 2% SDS, 10%
2-mercaptoethanol, 20% glycerol), heated at 100°C for 10 min, and sub-
jected to electrophoresis in 0.1% SDS–12% polyacrylamide gels (SDS-
PAGE). Gels were stained with Coomassie brilliant blue.
Proteolytic activity. For qualitative determination of proteolytic ac-
tivity,P. aeruginosa strains were grown in LB, diluted to anOD600 of1 in
saline, and spotted (5 l) onto Luria-Bertani agar (LA) plates containing
2% skim milk (Difco). Proteolytic activity was detected as a clear halo
around the bacterial patch after 18 h of growth at 37°C.
Western blot detection of Tf in HS and the PVD biosynthetic en-
zyme PvdA in P. aeruginosa cells.HS proteins and P. aeruginosa whole-
cell lysates were separated by SDS-PAGE and electrotransferred onto ni-
trocellulose filters (Hybond C extra; Amersham) using a semidry transfer
unit (Hoefer Scientific Instruments) for 1 h at 150 mA. Filters were
blocked with 2 TBST (100 mM Tris-HCl [pH 8.0], 1.0 M NaCl, 0.1%
Tween 20) containing 2% bovine serum albumin, washed with 2 TBST,
incubated with a monoclonal anti-PvdA antibody (25) or an anti-human
Tf rabbit polyclonal antibody (Epitomics) diluted 1:100 or 1:3,000 in 2
TBST, respectively. Proteins were detected with a secondary anti-mouse
(Promega) or anti-rabbit (Calbiochem) alkaline phosphatase-conjugated
antibody. Blots were developed with the 5-bromo-4-chloro-3-indoyl-
phosphate (BCIP) and nitroblue tetrazolium chloride (NBT) reagents for
colorimetric detection (Promega).
Detection of quorum sensing (QS) signal molecules. To determine
the production ofN-3-oxododecanoyl homoserine lactone (3OC12-HSL)
and N-butanoyl-L-homoserine lactone (C4-HSL), 100-l volumes of
overnight cultures of each clinical isolate diluted in LB at OD600 0.01 were
cocultured with 100-l volumes of overnight cultures of reporter strains
PA14-R3 for 3OC12-HSL and PAO-JP2 (pKD-rhlA) for C4-HSL (26, 27)
diluted in LB at anOD600 of 0.045.Microtiter plates (final volume, 200l)
were incubated at 37°C with shaking, and cell density (OD600) and biolu-
minescence (light counts per second)were simultaneouslymeasured after
6 h in a Wallac 1420 Victor3V multilabel plate reader (PerkinElmer).
Luminescence values were normalized by the cell density (OD600).
Statistical analyses. Spearman correlation coefficients (rs) were used
as a measure of the relative validity between P. aeruginosa growth in HS
and protein hydrolysis or PVD production. Student’s t test was used to
determine significant differences in Ga(NO3)3MICs, using the GraphPad
Prism software.
RESULTS
P. aeruginosa susceptibility to gallium is lower in HS than in an
iron-poor laboratory medium. The anti-P. aeruginosa activity of
Ga(NO3)3 was preliminarily tested in complement-free HS on 55
P. aeruginosa clinical isolates collected from respiratory secretions
of CF patients (27 isolates) and from a variety of pathological
samples from non-CF patients (28 isolates) (see Table S1 in the
supplemental material). All but four isolates, namely, SP18, SP20,
SP21, and FM1, grew in HS. P. aeruginosa growth in HS was in-
variably characterized by a long lag phase of 10 to 18 h and at-
tained stationary phase after 36 to 54 h (data not shown). TheMIC
of Ga(NO3)3 was determined both in HS and in the iron-free
Casamino Acids medium DCAA (17), for comparison. The great
majority of isolates (72%) displayed a 4-fold increase in
Ga(NO3)3 MIC in HS compared with that in DCAA (Fig. 1; see
also Table S1 in the supplemental material), indicating a reduced
susceptibility of P. aeruginosa to Ga(NO3)3 in HS.
Both proteases and PVD contribute to P. aeruginosa growth
in HS. The antibacterial activity of gallium depends on iron avail-
ability, being evident only under iron-limiting conditions (8, 11).
It was therefore surprising to observe a poor antibacterial activity
for Ga(NO3)3 in HS, where the free iron concentration is known
to be limiting for bacterial growth (1). This effect could be due to
the ability of P. aeruginosa to acquire iron from Tf via sidero-
phores, or proteases, or both (4, 28). Increased iron availability
would thus promote growth and ultimately counteract the anti-
bacterial activity of an iron-mimetic inhibitor, like Ga(NO3)3 (8–
11). Therefore, the ability of clinical isolates to hydrolyze serum
proteins and/or produce PVD was investigated. The amount of
FIG 1 Fold increase of the Ga(NO3)3 MICs in HS, relative to that in DCAA,
for 51 P. aeruginosa clinical isolates.
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hydrolyzed proteins wasmeasured inHS after bacterial growth, as
TCA-nonprecipitablematerial (Fig. 2A), and qualitatively verified
by SDS-PAGE analysis of serum proteins relative to the uninocu-
lated control (see Fig. S1 in the supplemental material). The
growth of P. aeruginosa clinical isolates in HS correlated well with
their ability to hydrolyze serum proteins (rs  0.87) (Fig. 2A),
while poor correlation was observed between PVD production
and growth in HS (rs  0.42) (Fig. 2B). These data suggest that
increased availability of nutrients (e.g., free iron and amino acids)
and the consequent P. aeruginosa growth promotion in HS pri-
marily depend on protein degradation rather than on PVD pro-
duction, at least during late growth, when protease activity and
PVD production were measured. Accordingly, Tf was completely
degraded in spent HS obtained fromHS-hydrolyzing strains such
as the type strain PAO1, as opposed to weak HS hydrolyzers, such
as the CF isolate TR1, regardless of the presence or absence of
exogenously added FeCl3 (Fig. 2C and see Fig. S1 in the supple-
mental material). Interestingly, both PAO1 and TR1 produced
PVD, as documented by their fluorescent phenotype in HS and
expression of the iron-repressible PvdA enzyme, implicated in an
early step of PVD biogenesis (Fig. 2C) (29). This observation con-
firms that HS is perceived by P. aeruginosa as an iron-poor envi-
ronment, inductive of PVD production.
Of note, significantly lowerHS proteolysis was observed for CF
than for non-CF isolates (P 	 0.05, chi-square test; data not
shown), consistentwith the notion thatP. aeruginosa isolates from
chronic CF infections generally display low protease activity (30).
To gain insight into the contribution of individual iron acqui-
sition systems to P. aeruginosa growth in HS, the reference strain
PAO1 and isogenic deletion mutants impaired in heme uptake
(hasR phuR [31]) and siderophore-dependent iron uptake
(pvdA, impaired in PVD biosynthesis [32]; pchD, impaired in
pyochelin biosynthesis [33], or pvdA pchD, defective in pro-
duction of both siderophores [34]) were cultured in HS supple-
mented or not with an excess of iron (Fig. 2D). Only the PVD-
defective mutants (pvdA and pvdA pchD) showed impaired
growth in HS compared with the wild type, whereas addition of
FeCl3 (100M) rescued the growth of the mutants to wild-type
levels (Fig. 2D). Conversely, mutations in heme uptake or pyo-
chelin biosynthesis genes did not affect bacterial growth in HS
(Fig. 2D).
PVD is essential for P. aeruginosa growth initiation in HS.
The above-described results prompted us to investigate whether
the lack of growth in HS of the clinical isolates SP18, SP20, SP21,
and FM1 was due to a defect in PVD production. These strains
displayed a PVD-defective phenotype when grown in the iron-
FIG 2 (A) Correlation analysis between hydrolysis of HS proteins and P. aeruginosa growth in HS. Hydrolyzed HS proteins were quantified as TCA-nonprec-
ipitable, Lowry-reactivematerial and are expressed as percentages relative to totalHS proteins. An arbitrary cutoff value of 10%of hydrolyzed serumproteinswas
set to discriminate between weak and strongHS-hydrolyzing isolates (dotted line). (B) Correlation analysis between pyoverdine (PVD) production (OD405) and
P. aeruginosa growth in HS. Black and white circles represent CF and non-CF isolates, respectively. Arrows indicate strains PAO1 and TR1, representative of HS
hydrolyzing and nonhydrolyzing isolates, respectively. The Spearman rank correlation coefficients (rs) are indicated. (C) Western blot analysis of Tf and PVD
biosynthetic enzyme (PvdA) levels in HS culture supernatants and bacterial cell lysates, respectively. P. aeruginosa strains PAO1 and TR1 were grown in HS
supplemented or not with 100 M FeCl3 [Fe(III) andFe(III), respectively]. PVD production was qualitatively assayed by fluorescence emission under UV
light. (D) Growth of P. aeruginosa PAO1mutants impaired in different iron uptake systems inHS (gray bars) and inHS supplemented with 100MFeCl3 (black
bars). In all experiments, the mean value of results for at least two independent microtiter plate assays was considered.
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poor minimal medium DCAA (Fig. 3) and were able to grow in
predigested HS (Fig. 3), where iron is released from Tf and avail-
able to bacteria (Fig. 3). Moreover, all isolates except FM1 grew in
HS supplemented with 100 M FeCl3. Notably, FM1 was also the
only strain that was impaired in protease production onmilk agar
plates (Fig. 3). Exogenously added PVD stimulated the growth of
the PAO1pvdAmutant inHS in a dose-dependentmanner, even
at concentrations far below the maximum PVD levels achievable
byP. aeruginosaPAO1 in iron-depleted laboratory cultures (
200
M) (19). These results support the essential role of PVD for P.
aeruginosa growth in HS.
QS-controlled proteases increase P. aeruginosa growth in
HS. The inability of protease-proficient P. aeruginosa isolates
SP18, SP20, and SP21 to grow in HS is in apparent contrast with
the good correlation observed between protease production and
growth in HS (Fig. 2A). Since the expression of protease in P.
aeruginosa is a growth phase-dependent phenomenon regulated
by quorum sensing (QS) (35), we hypothesized that bacteria need
to reach a certain cell density to allow the protease-dependent
growth increment. In this view, PVDmight play a prominent role
at early growth stages, when protease production is scarce. Then,
in response to increased cell density and QS, protease-mediated
iron mobilization from Tf would further support growth. To ad-
dress this point, we determined the growth inHSof aP. aeruginosa
PAO1 QS-defective mutant (lasR lasI) (36) and a protease-defec-
tivemutant (lasA lasB aprA) (37), both proficient in PVDproduc-
tion (data not shown). Both mutants produced barely detectable
levels of proteases and showed a ca. 3-fold reduction in growth
yields in HS, relative to that of the wild-type PAO1 (Fig. 4). Nota-
bly, both predigestion of HS and supplementation with 100 M
FeCl3 strongly stimulated the growth of QS- and protease-defec-
tive mutants (Fig. 4). These findings strongly suggest that QS-
controlled protease production provides P. aeruginosawith incre-
mental growth capabilities in HS, likely through proteolytic
mobilization of Tf-bound iron. Moreover, a transposon mutant
deficient in the iron- and PVD-regulated protease PrpL (38, 39)
showed significant growth reduction in HS and decreased hydro-
lysis of HS proteins (20% and 35%, respectively, relative to the
parental strain PAO1; data not shown), corroborating the impor-
tance of protease production for P. aeruginosa growth in HS.
HS proteolysis impairs gallium activity. As anticipated, the
growth of different P. aeruginosa clinical isolates in HS correlates
well with their ability to produce proteases. Consequently, we hy-
pothesized that proteolytic release of iron fromHS proteins could
be responsible for the loss of the antibacterial activity of gallium
(8–11). After an arbitrary cutoff value of 10% hydrolyzed HS pro-
teins was set (Fig. 2A, dotted line), isolates were split into two
groups, defined as strongHS hydrolyzers (27 isolates composed of
9CF and 18non-CF isolates) andweakHShydrolyzers (24 isolates
composed of 17 CF and 7 non-CF isolates). Notably, the median
Ga(NO3)3MIC for weak HS hydrolyzers was 16M, while strong
HS hydrolyzers displayed a median MIC of 64 M (Fig. 5A). In
line with this observation, the Ga(NO3)3 MICs of the protease-
FIG 3 Growth (OD600) of PVD-defective P. aeruginosa strains in HS supple-
mented with 100 MFeCl3 (black bars), predigested HS (dark gray bars), and
HS (light gray bars). Growth of the PAO1pvdAmutant inHSwas rescued by
addition of increasing concentrations of PVD. Growth values (OD600) for the
wild-type strain PAO1 were 3.39 0.32, 4.56  0.01, and 3.25  0.27 in HS
supplementedwith 100MFeCl3, predigestedHS, andHS, respectively.Qual-
itative data on PVDproduction inDCAA and proteolytic activity on skimmilk
agar plates are shown for each strain.
FIG 4 Growth (OD600) and hydrolysis of HS proteins (relative to total HS
proteins; diamonds) by P. aeruginosa PAO1 and lasR lasI and lasA lasB aprA
mutants, grown for 48 h at 37°C in HS (light gray bars), predigested HS (dark
gray bars), and HS supplemented with 100 M FeCl3 (black bars). Values
represent the mean (standard deviation) of results for three independent
assays. Standard deviations are not visible when the bars representing them are
smaller than the symbol of the corresponding data point.
FIG 5 MICs of Ga(NO3)3 for 51 P. aeruginosa clinical isolates grown for 48 h
inHS (A) and for 24 h inDCAA (B). PVD-defective isolates were not included.
For each isolate, the mean value of results for two independent assays was
considered. Isolateswere grouped according to their ability to hydrolyze serum
proteins (see Fig. 1A). The horizontal line is the median for each group. Black
and white circles represent CF and non-CF isolates, respectively. An asterisk
indicates a statistically significant difference (P 	 0.001; Student’s t test) be-
tween the two groups.
Bonchi et al.
5644 aac.asm.org September 2015 Volume 59 Number 9Antimicrobial Agents and Chemotherapy
 o
n







defective PAO1 lasR lasI and lasA lasB aprA mutants in HS were
reproducibly 2-fold lower than that of their parental strain (32
M versus 64 M). The lower inhibitory effect of Ga(NO3)3 on
strong HS hydrolyzers than on weak HS hydrolyzers (Fig. 5A)
confirms that proteolytic activity, most plausibly Tf degradation,
has a major impact on the anti-P. aeruginosa activity of Ga(NO3)3
in HS. This was corroborated by the finding that in predigested
HS, theMICofGa(NO3)3was
256Mfor all strains tested (data
not shown), and stimulation of bacterial growthwasmuch greater
forweakHShydrolyzers than strongHShydrolyzers (see Fig. S2 in
the supplemental material). Notably, weak and strong HS hydro-
lyzers displayed similar growth yields and Ga(NO3)3 susceptibili-
ties when grown in the Casamino Acids-based iron-poormedium
DCAA, where amino acids are readily available and proteolytic
activity is dispensable for bacterial growth (no complexes with
iron-binding proteins are present in this medium [17]) (Fig. 5B;
see Fig. S3A in the supplemental material). As expected, the effect
ofGa(NO3)3 inHSwas completely abrogated by the addition of an
excess of FeCl3 [Fe(III):Ga(III) molar ratio, 5:1]) (see Fig. S3B in
the supplemental material), and MICs of 
512 M were deter-
mined for all strains in MH, where the iron concentration is high
(14 M [40]).
DISCUSSION
InterferingwithP. aeruginosa ironmetabolism represents a prom-
ising strategy to develop novel therapeutic options, and the repur-
posing of gallium-based drugs has recently been discussed as an
alternative strategy for antibacterial chemotherapy (14).
In this work, we investigated the ability of Ga(NO3)3 to inhibit
the growth of P. aeruginosa in HS. We report that P. aeruginosa is
less susceptible to gallium-mediated growth inhibition inHS than
in an iron-poor laboratory medium (Fig. 1), as opposed to what
was recently reported for Acinetobacter baumannii, which is a
scarcely proteolytic species (18, 41, 42). This different behavior
depends on the ability of P. aeruginosa to acquire iron from Tf, by
means of the PVD siderophore and hydrolysis of HS proteins,
which ultimately provides sufficient iron to counteract gallium
inhibition. Upon testing a representative collection of diverse P.
aeruginosa clinical isolates, we report a very good correlation be-
tween HS proteolysis and the ability to grow in HS (Fig. 2A),
indicating that iron availability in HS no longer limits bacterial
growth when proteases are produced.
Interestingly, we found that clinical isolates and laboratory
strains defective in PVD production (namely SP18, SP20, SP21,
FM1, PAO1pvdApchD, and PAO1pvdA) cannot grow inHS
(Fig. 2 and 3), in line with previous findings (28). Since protease
production by P. aeruginosa is regulated by QS (35), we also ob-
served that QS- and protease-defective mutants were inhibited by
HS, although growth yieldswere restored to thewild-type levels by
predigestion of HS proteins or supplementation of HS with an
excess of FeCl3 (Fig. 4). Altogether, these data depict a scenario in
which PVD production is essential to ensure initial growth in HS,
while protease production, which likely starts during late growth
being regulated by QS, allows P. aeruginosa to reach higher cell
densities by making essential nutrients (e.g., iron and amino ac-
ids) readily available. Therefore, it appears that production of pro-
teases is necessary but per se insufficient to allow P. aeruginosa
growth in HS, since protease-proficient strains that are unable to
produce PVD do not grow in HS (Fig. 3). In contrast, protease-
deficient strains able to produce PVD grow in HS, albeit with
reduced yields (Fig. 4). Accordingly, we found that QS-deficient
clinical isolates impaired in protease production (about 15% in
our strain collection) could grow in HS when they were proficient
in PVD production (see Table S1 in the supplemental material).
Given the importance of protease production and iron release
fromTf for P. aeruginosa growth inHS, we observed that weakHS
hydrolyzers were more susceptible to gallium-mediated growth
inhibition in HS than strong HS hydrolyzers (Fig. 5A) and that
this difference was abolished when Ga(NO3)3 MICs were mea-
sured in DCAA (Fig. 5B) or in the presence of an excess of iron,
e.g., in MH and predigested HS.
Overall, our findings highlight the need for appropriate in vitro
conditions toassessgrowth inhibitionbyan ironmimetic.Compared
with conventional laboratorymedia (e.g., DCAA andMH), HS pro-
vides a more realistic environment to assess the antibacterial activity
of gallium (11). From a practical viewpoint, the Ga(NO3)3 concen-
trations required to inhibit the growth of the majority of P. aerugi-
nosa isolates in HS are very close to or even higher than those
achievable in plasma for cancer therapy. In fact, the recommended
dosing regimens for the treatment of cancer-related hypercalce-
mia attain a peak serum concentration of Ga(NO3)3 of ca. 28 M
(7, 43). This gallium concentration is insufficient to suppress the
growth in HS of highly proteolytic P. aeruginosa strains (Fig. 5A),
which predominate among non-CF isolates, thus raising concern
about the potential of Ga(NO3)3 in the treatment of systemic P.
aeruginosa infection. It should also be considered that because of
the high hemolytic activity of P. aeruginosa (44), some iron
sources such as heme could be more readily available in whole
blood. Thus, it cannot be excluded that iron acquisition strategies
other than pyoverdine (e.g., heme uptake) could counteract the
iron-mimetic activity of gallium in vivo. On the other hand, the
antibacterial activity of the complement and the host’s immune
system are likely to synergize with gallium in vivo. Indeed,
Ga(NO3)3 provided effective protection from P. aeruginosa lung
infection in mice (8), and preliminary results point to its efficacy
in reducing bacterial load during CF lung infection (13). How-
ever, the strain-dependent ability of P. aeruginosa tomobilize iron
from the host iron-containing proteins and grow in serum (or
other body fluids) should be taken into account in the future de-
velopment of gallium-based antibacterial therapies.
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